Idiopathic non-specific interstitial pneumonia: a brief review
DOI:
https://doi.org/10.18203/2394-6040.ijcmph20250336Keywords:
Idiopathic NSIP, Connective tissue disease, Ground glassingAbstract
Non-specific interstitial pneumonia (NSIP) is one of the better variants of interstitial lung disease in terms of outcomes. Timely diagnosis with early treatment has excellent 5-year survival figures. Typical clinical symptoms and radiologic findings makes diagnosis easy. Ruling out various associated connective tissue disease (CTD) is of paramount importance as they are amenable to immunosuppressant therapies. Majority of cases still remain idiopathic which forms the major chunk of NSIP pool. This article highlights the natural history, epidemiology and key differentiating features of NSIP and current treatment options.
Metrics
References
Fukuoka J, Tanaka T, Tabata K, Kashima Y. Reproducibility of the ATS/ERS classification of idiopathic interstitial pneumonias. Pathology. 2014;46:S37-8. DOI: https://doi.org/10.1097/01.PAT.0000454214.43092.be
Hino T, Lee KS, Yoo H, Han J, Franks TJ, Hatabu H. Interstitial lung abnormality (ILA) and nonspecific interstitial pneumonia (NSIP). Eur J Radiol Open. 2021;8:100336.
Fewins HE, McGowan I, Whitehouse GH, Williams J, Mallya R. High definition computed tomography in rheumatoid arthritis associated pulmonary disease. Br J Rheumatol. 1991;30:214-6. DOI: https://doi.org/10.1093/rheumatology/30.3.214
Travis WD, Costabel U, Hansell DM, King Jr TE, Lynch DA, Nicholson AG, et al. An official American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med. 2013;188(6):733-48. DOI: https://doi.org/10.1164/rccm.201308-1483ST
Adegunsoye A, Ryerson CJ. Diagnostic classification of interstitial lung disease in clinical practice. Clin Chest Med. 2021;42(2):251-61. DOI: https://doi.org/10.1016/j.ccm.2021.03.002
Koo SM, Kim SY, Choi SM, Lee HK; Korean Interstitial Lung Diseases Study Group. Korean Guidelines for Diagnosis and Management of Interstitial Lung Diseases: Part 5. Connective Tissue Disease Associated Interstitial Lung Disease. Tuberc Respir Dis (Seoul). 2019;82(4):285-97. DOI: https://doi.org/10.4046/trd.2019.0009
Belloli EA, Beckford R, Hadley R, Flaherty KR. Idiopathic non‐specific interstitial pneumonia. Respirology. 2016;21(2):259-68. DOI: https://doi.org/10.1111/resp.12674
Roongta R, Chattopadhyay A. Epidemiology and prevalence of connective tissue disorder–interstitial lung disease: World and Indian data. Indian J Rheumatol. 2021;16(Suppl 1):S3-9. DOI: https://doi.org/10.4103/0973-3698.332973
Teoh AK, Corte TJ. Nonspecific interstitial pneumonia. In: Seminars in Respiratory and Critical Care Medicine. Thieme Medical Publishers. 2020;41(2):184-201. DOI: https://doi.org/10.1055/s-0040-1708499
Mira-Avendano I, Abril A, Burger CD, Dellaripa PF, Fischer A,Gotway MB, et al. Interstitial Lung Disease and Other Pulmonary Manifestations in Connective Tissue Diseases. Mayo Clin Proc. 2019;94:309-25. DOI: https://doi.org/10.1016/j.mayocp.2018.09.002
Bansal D, Mukati S. Epidemiology of Interstitial Lung Disease in Tertiary Care Centre of Central India. J Adv Med Dent Sci Res. 2020;8(7):79-81.
Skeoch S, Weatherley N, Swift AJ, Oldroyd A, Johns C, Hayton C, et al. Drug-induced interstitial lung disease: a systematic review. J Clin Med. 2018;7(10):356. DOI: https://doi.org/10.3390/jcm7100356
Spagnolo P, Bonniaud P, Rossi G, Sverzellati N, Cottin V. Drug-induced interstitial lung disease. Eur Respir J. 2022;60(4). DOI: https://doi.org/10.1183/13993003.02776-2021
Ebner L, Christodoulidis S, Stathopoulou T, Geiser T, Stalder O, Limacher A, et al. Meta-analysis of the radiological and clinical features of Usual Interstitial Pneumonia (UIP) and Nonspecific Interstitial Pneumonia (NSIP). PLoS One. 2020;15(1):e0226084. DOI: https://doi.org/10.1371/journal.pone.0226084
Ciancio N, Pavone M, Torrisi SE, Vancheri A, Sambataro D, Palmucci S, et al. Contribution of pulmonary function tests (PFTs) to the diagnosis and follow up of connective tissue diseases. Multidiscip Respir Med. 2019;14:1. DOI: https://doi.org/10.1186/s40248-019-0179-2
Heukels P, Moor CC, Von der Thüsen JH, Wijsenbeek MS, Kool MJ. Inflammation and immunity in IPF pathogenesis and treatment. Respir Med. 2019;147:79-91. DOI: https://doi.org/10.1016/j.rmed.2018.12.015
Nishikiori H, Kuronuma K, Hirota K, Yama N, Suzuki T, Onodera M, et al. Deep-learning algorithm to detect fibrosing interstitial lung disease on chest radiographs. Eur Respir J. 2023;61(2). DOI: https://doi.org/10.1183/13993003.02269-2021
Chung JH, Cox CW, Montner SM, Adegunsoye A, Oldham JM, Husain AN, et al. CT features of the usual interstitial pneumonia pattern: differentiating connective tissue disease–associated interstitial lung disease from idiopathic pulmonary fibrosis. Am J Roentgenol. 2018;210(2):307-13. DOI: https://doi.org/10.2214/AJR.17.18384
Kwon BS, Choe J, Do KH, Hwang HS, Chae EJ, Song JW. Computed tomography patterns predict clinical course of idiopathic pulmonary fibrosis. Respir Res. 2020;21(1):1-9. DOI: https://doi.org/10.1186/s12931-020-01562-2
Kebbe J, Abdo T. Interstitial lung disease: the diagnostic role of bronchoscopy. Journal of thoracic disease. 2017;9(10):S996. DOI: https://doi.org/10.21037/jtd.2017.06.39
Yoo H, Hino T, Hwang J, Franks TJ, Han J, Im Y, et al. Connective tissue disease-related interstitial lung disease (CTD-ILD) and interstitial lung abnormality (ILA): Evolving concept of CT findings, pathology and management. Eur J Radiol Open. 2022;9:100419. DOI: https://doi.org/10.1016/j.ejro.2022.100419
Cottin V, Hirani NA, Hotchkin DL, Nambiar AM, Ogura T, Otaola M, et al. Presentation, diagnosis and clinical course of the spectrum of progressive-fibrosing interstitial lung diseases. Eur Respir Rev. 2018;27(150). DOI: https://doi.org/10.1183/16000617.0076-2018
Nicholson AG, Colby TV, du Bois RM, Hansell DM, Wells AU. The prognostic significance of the histologic pattern of inter¬stitial pneumonia in patients presenting with the clinical en¬tity of cryptogenic fibrosing alveolitis. Am J Respir Crit Care Med. 2000;162:2213-7. DOI: https://doi.org/10.1164/ajrccm.162.6.2003049
Kligerman SJ, Groshong S, Brown KK, Lynch DA. Nonspecific interstitial pneumonia: radiologic, clinical, and pathologic considerations. Radiographics. 2009;29:73-87. DOI: https://doi.org/10.1148/rg.291085096
Collins B, Raghu G. Interstitial pneumonia with autoimmune features: the new consensus-based definition for this cohort of patients should be broadened. Eur Respir J. 2016;47:1293-5. DOI: https://doi.org/10.1183/13993003.02084-2015
Kinder BW, Collard HR, Koth L, Daikh DI, Wolters PJ, Elicker B, Jones KD, King Jr TE. Idiopathic nonspecific interstitial pneumonia: lung manifestation of undifferentiated connective tissue disease? Am J Respir Crit Care Med. 2007;176(7):691-7. DOI: https://doi.org/10.1164/rccm.200702-220OC
Wells AU, Kokosi M, Karagiannis K. Treatment strategies for idiopathic interstitial pneumonias. Curr Opin Pulm Med 2014; 20:442-8. DOI: https://doi.org/10.1097/MCP.0000000000000085
Mathai SC, Danoff SK. Management of interstitial lung disease associated with connective tissue disease. BMJ. 2016;24:352. DOI: https://doi.org/10.1136/bmj.h6819
Bradley B, Branley HM, Egan JJ, Greaves MS, Hansell DM, Harrison NK, et al. Interstitial lung disease guideline: the British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society. Thorax. 2008;63(5):v1-58. DOI: https://doi.org/10.1136/thx.2008.101691
Tomassetti S, Ryu JH, Piciucchi S, Chilosi M, Poletti V. Nonspecific interstitial pneumonia: what is the optimal approach to management? In Seminars in respiratory and critical care medicine. Thieme Medical Publishers. 2016;37(03):378-94. DOI: https://doi.org/10.1055/s-0036-1583176
Vacchi C, Sebastiani M, Cassone G, Cerri S, Della Casa G, Salvarani C, et al. Therapeutic options for the treatment of interstitial lung disease related to connective tissue diseases. A narrative review. J Clin Med. 2020;9(2):407. DOI: https://doi.org/10.3390/jcm9020407
Watanabe K, Higuchi K, Ninomiya K, Ohshima T, Aritomi T, Kawabata Y, et al. Steroid treatment based on the findings of transbronchial biopsy in idiopathic interstitial pneumonia. Eur Respir J. 2002;20:1213-9. DOI: https://doi.org/10.1183/09031936.02.00269302
Arai T, Tachibana K, Sugimoto C, Inoue Y, Tokura S, Okuma T, et al. High‐dose prednisolone after intravenous methylprednisolone improves prognosis of acute exacerbation in idiopathic interstitial pneumonias. Respirology. 2017;22(7):1363-70. DOI: https://doi.org/10.1111/resp.13065
Park IN, Jegal Y, Kim DS, Do KH, Yoo B, Shim TS, et al. Clinical course and lung function change of idiopathic nonspecific interstitial pneumonia. Eur Respir J. 2009;33:68-76. DOI: https://doi.org/10.1183/09031936.00158507
Huo Z, Li J, Li S, Zhang H, Jin Z, Pang J, et al. Organizing pneumonia components in non‐specific interstitial pneumonia (NSIP): a clinicopathological study of 33 NSIP cases. Histopathology. 2016;68(3):347-55. DOI: https://doi.org/10.1111/his.12761
Hino T, Lee KS, Yoo H, Han J, Franks TJ, Hatabu H. Interstitial lung abnormality (ILA) and nonspecific interstitial pneumonia (NSIP). Eur J Radiol Open. 2021;8:100336. DOI: https://doi.org/10.1016/j.ejro.2021.100336
Wang J, Wang X, Qi X, Sun Z, Zhang T, Cui Y, et al. The efficacy and safety of pirfenidone combined with immunosuppressant therapy in connective tissue disease-associated interstitial lung disease: a 24-week prospective controlled cohort study. Front Med. 2022;9:871861. DOI: https://doi.org/10.3389/fmed.2022.871861
Barnes H, Holland AE, Westall GP, Goh NS, Glaspole IN. Cyclophosphamide for connective tissue disease–associated interstitial lung disease. Cochrane Database Syst Rev. 2018;1(1):CD010908. DOI: https://doi.org/10.1002/14651858.CD010908.pub2
Schulze AB, Evers G, Kümmel A, Rosenow F, Sackarnd J, Hering JP, et al. Cyclophosphamide pulse therapy as treatment for severe interstitial lung diseases. Sarcoidosis Vasc Diffuse Lung Dis. 2019;36(2):157.
Keir GJ, Maher TM, Ming D, Abdullah R, de Lauretis A, Wick¬remasinghe M, et al. Rituximab in severe, treatment-refracto¬ry interstitial lung disease. Respirology. 2014;19:353-9. DOI: https://doi.org/10.1111/resp.12214
Bejan-Angoulvant T, Naccache JM, Caille A, Borie R, Nunes H, Ferreira M, et al. Evaluation of efficacy and safety of rituximab in combination with mycophenolate mofetil in patients with nonspecific interstitial pneumonia non-responding to a first-line immunosuppressive treatment (EVER-ILD): a double-blind placebo-controlled randomized trial. Respir Med Res. 2020;78:100770. DOI: https://doi.org/10.1016/j.resmer.2020.100770
Atienza-Mateo B, Remuzgo-Martínez S, Prieto-Peña D, Mora Cuesta VM, Iturbe-Fernández D, Llorca J, et al. Rituximab in the treatment of interstitial lung disease associated with autoimmune diseases: experience from a single referral center and literature review. J Clin Med. 2020;9(10):3070. DOI: https://doi.org/10.3390/jcm9103070
Kreuter M, Wälscher J, Behr J. Antifibrotic drugs as treatment of nonidiopathic pulmonary fibrosis interstitial pneumonias: the time is now (?). Curr Opin Pulm Med. 2017;23(5):418-25. DOI: https://doi.org/10.1097/MCP.0000000000000408
Jegal Y, Kim DS, Shim TS, Lim CM, Do Lee S, Koh Y, et al. Physiology is a stronger predictor of survival than pathology in fibrotic interstitial pneumonia. Am J Respir Crit Care Med. 2005;171(6):639-44. DOI: https://doi.org/10.1164/rccm.200403-331OC
Ryerson CJ, Vittinghoff E, Ley B, Lee JS, Mooney JJ, Jones KD, et al. Predicting survival across chronic interstitial lung disease: the ILD-GAP model. Chest. 2014;145(4):723-8. DOI: https://doi.org/10.1378/chest.13-1474
Travis WD, Matsui K, Moss J, Ferrans VJ. Idiopathic nonspecific interstitial pneumonia: prognostic significance of cellular and fibrosing patterns: survival comparison with usual interstitial pneumonia and desquamative interstitial pneumonia. Am J Surg Pathol. 2000;24(1):19. DOI: https://doi.org/10.1097/00000478-200001000-00003
Obi ON, Judson MA, Birring SS, Maier LA, Wells AU, Lower EE, et al. Assessment of dyspnea in sarcoidosis using the Baseline Dyspnea Index (BDI) and the Transition Dyspnea Index (TDI). Respir Med. 2022;191:106436. DOI: https://doi.org/10.1016/j.rmed.2021.106436
Desai U, Bacche J, Joshi JM. The Novel Measurements and Correlations for Pulmonary Function Tests (TNMC-PFT) in interstitial lung diseases (ILD)-Using technology to simplify patient care. Pneumon. 2019;32(4):132-6.
Flaherty KR, Mumford JA, Murray S, Kazerooni EA, Gross BH, Colby TV, et al. Prognostic implications of physiologic and radiographic changes in idiopathic interstitial pneumonia. Am J Respir Crit Care Med. 2003;168(5):543-8. DOI: https://doi.org/10.1164/rccm.200209-1112OC